



# Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset

Loredana Storelli, PhD,<sup>1</sup> Elisabetta Pagani, MSc,<sup>1</sup> Patrizia Pantano, MD,<sup>2,3</sup> Claudia Piervincenzi, PhD,<sup>2</sup> Gioacchino Tedeschi, MD,<sup>4</sup> Antonio Gallo, PhD,<sup>4</sup> Nicola De Stefano, PhD,<sup>5</sup> Marco Battaglini, PhD,<sup>5</sup> Maria A. Rocca, PhD,<sup>1,6,7</sup>  and Massimo Filippi, MD,<sup>1,6,7,8,9\*</sup>  for the INNI Network<sup>†</sup>

**Background:** Current therapeutic strategies in multiple sclerosis (MS) target neurodegeneration. However, the integration of atrophy measures into the clinical scenario is still an unmet need.

**Purpose:** To compare methods for whole-brain and gray matter (GM) atrophy measurements using the Italian Neuroimaging Network Initiative (INNI) dataset.

**Study Type:** Retrospective (data available from INNI).

**Population:** A total of 466 patients with relapsing–remitting MS (mean age =  $37.3 \pm 10$  years, 323 women) and 279 healthy controls (HC; mean age =  $38.2 \pm 13$  years, 164 women).

**Field Strength/Sequence:** A 3.0-T, T1-weighted (spin echo and gradient echo without gadolinium injection) and T2-weighted spin echo scans at baseline and after 1 year (170 MS, 48 HC).

**Assessment:** Structural Image Evaluation using Normalization of Atrophy (SIENA-X/XL; version 5.0.9), Statistical Parametric Mapping (SPM-v12); and Jim-v8 (Xinapse Systems, Colchester, UK) software were applied to all subjects.

**Statistical Tests:** In MS and HC, we evaluated the intraclass correlation coefficient (ICC) among FSL-SIENA(XL), SPM-v12, and Jim-v8 for cross-sectional whole-brain and GM tissue volumes and their longitudinal changes, the effect size according to the Cohen's *d* at baseline and the sample size requirement for whole-brain and GM atrophy progression at different power levels (lowest = 0.7, 0.05 alpha level). False discovery rate (Benjamini–Hochberg procedure) correction was applied. A *P* value <0.05 was considered statistically significant.

**Results:** SPM-v12 and Jim-v8 showed significant agreement for cross-sectional whole-brain (ICC = 0.93 for HC and ICC = 0.84 for MS) and GM volumes (ICC = 0.66 for HC and ICC = 0.90) and longitudinal assessment of GM atrophy (ICC = 0.35 for HC and ICC = 0.59 for MS), while no significant agreement was found in the comparisons between whole-brain and GM volumes for SIENA-X/XL and both SPM-v12 (*P* = 0.19 and *P* = 0.29, respectively) and Jim-v8 (*P* = 0.21 and *P* = 0.32, respectively). SPM-v12 and Jim-v8 showed the highest effect size for cross-sectional GM atrophy (Cohen's

View this article online at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com/doi/10.1002/jmri.28616). DOI: 10.1002/jmri.28616

Received Nov 21, 2022, Accepted for publication Jan 12, 2023.

\*Address reprint requests to: M.F., Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy. E-mail: [filippi.massimo@hsr.it](mailto:filippi.massimo@hsr.it)

<sup>†</sup>INNI network: Milan: Paola Valsasina, Mauro Sibilja, Paolo Preziosa, Olga Marchesi; Naples: Alvino Bisecco, Alessandro d'Ambrosio, Manuela Altieri, Rocco Capuano; Rome: Silvia Tommasin, Serena Ruggieri, Nikolaos Petsas, Costanza Gianni; Siena: Maria Laura Stromillo, Rosa Cortese; Italian Multiple Sclerosis Foundation: Paola Zaratini.

Grant sponsor: This study was partially supported by Fondazione Italiana Sclerosi Multipla with a research fellowship (FISM 2019/BR/009) and a research grant (FISM2019/S/3), and financed or co-financed with the '5 per mille' public funding.

From the <sup>1</sup>Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>2</sup>Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy; <sup>3</sup>IRCCS NEUROMED, Pozzilli, Italy; <sup>4</sup>Department of Advanced Medical and Surgical Sciences, and 3T MRI-Center, University of Campania "Luigi Vanvitelli", Naples, Italy; <sup>5</sup>Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; <sup>6</sup>Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>7</sup>Vita-Salute San Raffaele University, Milan, Italy; <sup>8</sup>Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; and <sup>9</sup>Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy

Additional supporting information may be found in the online version of this article

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

$d = -0.63$  and  $-0.61$ ). Jim-v8 and SIENA(XL) showed the smallest sample size requirements for whole-brain (58) and GM atrophy (152), at 0.7 power level.

**Data Conclusion:** The findings obtained in this study should be considered when selecting the appropriate brain atrophy pipeline for MS studies.

**Evidence Level:** 4.

**Technical Efficacy:** Stage 1.

J. MAGN. RESON. IMAGING 2023.

Multiple sclerosis (MS) is no longer considered an exclusively inflammatory and demyelinating disease of the central nervous system, since neurodegeneration is also a major pathological hallmark.<sup>1</sup> Currently, MRI is the most common diagnostic and research tool in MS, which is capable of noninvasively quantifying neurodegeneration especially through measures of atrophy.<sup>2</sup>

Using MRI, it has been demonstrated that gray matter (GM) atrophy is relevant in MS for explaining clinical disability, cognitive impairment, and clinical evolution of the disease.<sup>3–5</sup> Moreover, the no evidence of disease activity (NEDA) status, which is defined by the absence of MRI activity (no appearance of new lesions on T2-weighted and gadolinium-enhancing lesions on T1-weighted sequences), relapses, and disability progression (included in NEDA-3), is upgraded to NEDA-4.<sup>6</sup> This proposed measure includes whole-brain atrophy assessment (brain volume loss  $\leq 0.4\%$ ), which reflects the neurodegenerative burden of the disease associated with disease progression and irreversible disability.<sup>6</sup> Current MS therapeutic strategies target neurodegeneration and the promotion of neuroprotection.<sup>7–9</sup>

The improvement of image analysis techniques for the reliable estimation of whole-brain and GM atrophy to be used for individualized treatment decisions is still an open area of research.<sup>2</sup> Specifically, these measures have still not found clinical application, because of time-consuming procedures and technical or disease-related challenges, due to high image quality requirements and the presence of MS lesions.<sup>2,10,11</sup> In a previous study, the accuracy and precision of available methods for whole-brain and GM atrophy quantification have been compared by using a test–retest dataset and simulated brain MRI of MS patients, with the aim to provide guidelines for selecting suitable software applications for atrophy measurement.<sup>11</sup> However, the existing automatic methods, as demonstrated also in other similar studies, are not reproducible enough to allow the monitoring of atrophy changes in individual patients.<sup>11–15</sup> Moreover, the application to multicenter data and larger samples should also be evaluated to confirm previous results,<sup>11,15</sup> in an attempt to formulate updated guidelines for the selection of atrophy tools, with the aim of technical improvements and future clinical integration. Specifically, the majority of previous studies of atrophy quantification in MS (both global and regional) have enrolled only small numbers of patients

(unlikely to be representative of the whole spectrum of the disease) and healthy controls (HC) acquired at a single center with the same MRI protocol.<sup>12,14,16–19</sup>

With the current study, we aimed to compare a set of common methods for whole-brain and GM atrophy measurements, taking advantage of the large multi-center dataset from the Italian Neuroimaging Network Initiative (INNI), to guide future users in the selection of an appropriate pipeline for MS studies, moving toward the use of brain atrophy measures in everyday clinical practice.

## Materials and Methods

Ethics approval was received from the local Institutional Review Board at each Research Center, and written informed consent was obtained from all subjects.

## Subjects

The INNI initiative has supported the creation of a repository where 3-T MRI, clinical, and neurophysiological data from MS patients and HC are collected from four Italian Research Centers in the MS field, with the main goal of improving the application of MRI to identifying novel MRI biomarkers for monitoring the disease course.<sup>20</sup>

We retrospectively studied 466 MS patients with a relapsing–remitting (RR) clinical phenotype<sup>21</sup> and 279 HC collected by INNI from four centers identified here as A, B, C, and D. Inclusion/exclusion criteria for all subjects (patients and HC) were as follows: no contraindications for MRI, no history of alcohol or substance abuse, no neurologic diseases (other than MS in the patients), and no psychiatric diseases.

The Expanded Disability Status Scale (EDSS) scores have been also collected for MS patients in order to assess their clinical disability status and the distribution among the centers. Demographic and clinical characteristics of patients and HC at the baseline visit are reported in Table 1.

Of this population, 170 MS patients and 48 HC underwent a follow-up re-evaluation 1 year after the baseline. At follow-up, all patients had been relapse-free and steroid-free for at least 1 month before the MRI acquisition.

At baseline, the group of patients with the follow-up visit were age- and sex-matched, as well as clinically matched according to the EDSS score compared to those who had the baseline visit only (median = 1.5, range = 0–4,  $P = 0.1$  compared to patients with baseline visit only).

## MRI Acquisitions

Baseline and follow-up brain MRI scans were obtained from each participating Center using 3.0-T scanners. Three-dimensional

**TABLE 1. Main Demographic and Clinical Findings in HCs and RRMS Patients at the Baseline Visit**

	HC	RRMS	<i>P</i>
All centers	( <i>n</i> = 279)	( <i>n</i> = 466)	
Females/males	164/115	323/143	<b>0.003<sup>a</sup></b>
Mean age (SD)	38 (13)	37 (10)	0.71 <sup>b</sup>
Mean median disease duration (range) (years)	-	9.5 8 (0–42)	-
Median EDSS (range)	-	1.5 (0–4.5)	-
Median T2 LV (range) (mL)	0.1 (0–0.5)	3.9 (0.1–40.7)	<b>&lt;0.001<sup>b</sup></b>
Center A	( <i>n</i> = 122)	( <i>n</i> = 215)	
Females/males	69/53	139/76	0.09 <sup>a</sup>
Mean age (SD)	36 (13)	37 (11)	0.47 <sup>b</sup>
Mean median disease duration (range) (years)	-	9.3 8.0 (2–30)	-
Median EDSS (range)	-	2 (0–4)	-
Median T2 LV (range) (mL)	0.1 (0–0.3)	3.5 (0.5–33.8)	<b>&lt;0.001<sup>b</sup></b>
Center B	( <i>n</i> = 59)	( <i>n</i> = 57)	
Females/males	38/21	40/17	0.50 <sup>a</sup>
Mean age (SD)	43 (13)	39 (10)	0.33 <sup>b</sup>
Mean median disease duration (range) (years)	-	11.8 9.5 (1–42)	-
Median EDSS (range)	-	2 (1–4)	-
Median T2 LV (range) (mL)	0.2 (0–0.5)	3.1 (0.2–30.8)	<b>&lt;0.001<sup>b</sup></b>
Center C	( <i>n</i> = 72)	( <i>n</i> = 115)	
Females/males	41/31	86/29	<b>0.01<sup>a</sup></b>
Mean age (SD)	36 (13)	38 (9)	<b>0.04<sup>b</sup></b>
Mean median disease duration (range) (years)	-	0.5 9.5 (0–27)	-
Median EDSS (range)	-	2 (0–4)	-
Median T2 LV (range) (mL)	0.1 (0–0.3)	4.3 (0.4–32.9)	<b>&lt;0.001<sup>b</sup></b>
Center D	( <i>n</i> = 26)	( <i>n</i> = 79)	
Females/males	17/9	58/21	0.43 <sup>a</sup>
Mean age (SD)	40 (9)	38 (10)	<b>0.32<sup>b</sup></b>
Mean median disease duration (range) (years)	-	7.9 6.5 (1–22)	-
Median EDSS (range)	-	1.5 (0–4.5)	-
Median T2 LV (range) (mL)	0.07 (0–0.2)	2.9 (0.1–22.2)	<b>&lt;0.001<sup>b</sup></b>

SD = standard deviation; HC = healthy controls; RRMS = relapsing–remitting multiple sclerosis; EDSS = Expanded Disability Status Scale; LV = lesion volume.  
<sup>a</sup>Pearson's chi-square test.  
<sup>b</sup>Mann–Whitney test.  
 Bold is for significant values.

(3D) T1-weighted (without gadolinium injection) and T2-weighted scans were acquired at each Center using a local protocol and the same MRI scanner at the follow-up acquisitions.

We describe the principal pulse sequence parameters in Table 2, although these are more extensively reported elsewhere.<sup>22</sup> Although protocols were not standardized, the 3D T1-weighted

sequence resulted in similar resolution and coverage among centers.<sup>22</sup>

### Image Analyses

Standardized preprocessing was systematically performed on all INNI MRI data, including a procedure for quality control described in detail elsewhere.<sup>22</sup> Briefly, steps of such a procedure included: conversion from DICOM to NIFTI image format; check and monitoring of head positioning; evaluation of image distortions and signal inhomogeneities; evaluation of the presence of artifacts and decision about inclusion/exclusion from the final dataset; for patients with MS, check (and editing, if needed) of T2 lesion masks sent from peripheral sites; co-registration of T2 lesion masks on high-resolution T1-weighted scans, and lesion refilling. During quality control of the longitudinal data, 8 HC and 17 MS patients were excluded for the follow-up scans due to the presence of image artifacts, poor repositioning, or insufficient coverage of the brain. Thus, 279 HC and 466 MS patients were included in the cross-sectional analysis; while 40 HC and 153 MS patient were finally included in the longitudinal analysis.

All sagittal acquisitions were reoriented to the axial plane, and for the 3D T1-weighted images the portion of the neck extending below the cerebellum was cropped. Focal T2-hyperintense white matter (WM) lesions had already been manually identified according to standardized procedures<sup>23</sup> and segmented by an expert neurologist (with more than 5 years of experience in MRI) from each participating Center. Lesion volumes were automatically extracted as the number of non-zero voxels in the binary masks of WM lesions multiplied by the voxel size.

In our study, baseline T1-weighted images after applying the lesion-filling technique implemented within the Functional MRI of the Brain (FMRIB) Software Library (FSL; version 5.0.9; <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki>),<sup>24</sup> in order to account for the presence of black holes, were used as input to the toolbox for cross-sectional whole-brain and GM tissue volumes extraction. For longitudinal atrophy quantification, both baseline and follow-up T1-weighted images (after lesion filling) were used as an input to all compared pipelines, in order to assess changes in whole-brain and GM atrophy over time. These cross-sectional and longitudinal (for those with follow-up) analyses were performed for each subject enrolled for this study (both MS and HC).

The pipelines selected for this study were those that were specifically developed for volumetric brain tissue segmentation and atrophy assessment on MRI data (cross-sectional and longitudinal). Moreover, for the quantification of atrophy of the whole brain and GM, we decided to compare the best-performing methods as obtained from a previous study.<sup>11</sup> Thus, given the good performance obtained from the previous comparative study, we used the same custom longitudinal version of Statistical Parametric Mapping (SPM-v12; <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) for atrophy quantification.<sup>11</sup> Moreover, a recently proposed extension from FMRIB FSL for longitudinal GM and WM atrophy assessment (Structural Image Evaluation, using Normalization of Atrophy [SIENA-XL]; version not released; <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA>),<sup>25</sup> and a new commercial software package for brain tissues atrophy quantification (Jim version 8, Xinapse Systems, Colchester, UK)<sup>26</sup>

were also included. In detail, the three following packages were compared and evaluated according to the results on whole-brain and GM tissue volumes and their longitudinal changes:

- SIENA(X)/SIENA-XL, FSL version 5.0.9 (SIENA-XL has been provided by developers upon reasonable request), University of Oxford, UK.<sup>25,27</sup>
- SPM toolbox version 12, Matlab (Release 2012a, MathWorks, University College London, UK).<sup>28</sup> For SPM-v12 longitudinal atrophy assessment, we need to point out that the pipeline was built in-house using a combination of the longitudinal pairwise registration (a tool already implemented in SPM) and the Jacobian integration technique (see Supplemental Material S1).
- Brain Atrophy Toolbox, Jim version 8 (Xinapse Systems, Colchester, UK).<sup>26</sup>

An automatic procedure is implemented within all these tools, which are extensively described in the Supplemental Material S1 for each software compared. Thus, after the previously described preprocessing steps on T1-weighted input images, we ran the automatic installed tools with default/recommended parameters.

The methods implemented within each automatic pipeline are extensively described in the Supplemental Material S1. The methods compared have computer processing times ranging from a minimum of 15 minutes for SPM-v12 and 20–30 minutes for Jim-v8 cross-sectional pipelines, to a maximum of 50–60 minutes for SIENAX on a computer with an Intel Xeon 12 core processor (Intel, Santa Clara, California, USA), 16 GB RAM and a Quadro K600 GPU (NVIDIA, Santa Clara), running CentOS Linux 7.

### Statistical Analysis

Statistical analysis was performed using the R software package (version 3.1.1; The R Project for Statistical Computing; <https://www.r-project.org/>). Demographic data and T2 lesion volumes were compared between groups using the  $\chi^2$  Pearson test for categorical variables and the Mann–Whitney U or t-tests for continuous variables. We evaluated the intraclass correlation coefficient (ICC), to assess the strength of the agreement among the different software packages based on whole-brain and GM atrophy measures (both cross sectional and longitudinal). The ICC was also evaluated separately for each center for cross-sectional whole-brain and GM segmentations in order to check for possible bias due to the different MRI acquisitions at each Center and/or MRI sequences. Between-group differences (center-adjusted) in whole-brain and GM cross-sectional volumes for the different software packages were expressed as effect size, calculated according to the Cohen's d definition.<sup>29</sup>

The sample size requirements at three different power levels (lowest = 0.7) for detecting a significant difference in the rates of whole-brain and GM atrophy progression between HC and MS at the 0.05 alpha level were estimated for each software package. False discovery rate (Benjamini–Hochberg procedure) correction was applied. A *P* value <0.05 was considered statistically significant.

## Results

### Demographic and Clinical Features

Table 1 summarizes the main demographic and clinical characteristics of the subject groups at the baseline visit.

TABLE 2. MRI acquisition parameters for each research Center participating in the INNI

Scanner	Center A		Center B		Center C		Center D	
	Philips Intera 8-channel head	Philips Intera 8-channel head	GE signa HDxt 8-channel head	Siemens Verio 12-channel head	Philips Achieva 32-channel head	Siemens Verio 12-channel head	Philips Achieva 32-channel head	Philips Achieva 32-channel head
Coil	Dual-echo	T1w FFE	FLAIR	T1w IR-FSPGR	Dual-echo	T1w MPRAGE	Dual-echo	T1w TFE
Coil	8-channel head coil	8-channel head coil	8-channel head coil	8-channel head coil	12-channel head coil	12-channel head coil	32-channel head coil	32-channel head coil
Plane	Axial	Axial	Axial	Sagittal	Axial	Sagittal	Axial	Axial
Voxel (mm <sup>3</sup> )	1 × 1 × 3	1 × 1 × 1	1 × 1 × 3	1 × 1 × 1.2	1 × 1 × 4	1 × 1 × 1	1 × 1 × 3	1 × 1 × 1
FOV (mm <sup>2</sup> )	243 × 243	230 × 230	256 × 256	256 × 256	220 × 220	256 × 256	240 × 240	256 × 256
TR (msec)	2910	25	9002	6.988	5310	1900	4000	10
TE (msec)	16–80	4.6	120	2.85	10–103	2.9	15–100	3.9
TI (msec)	–	–	2500	650	–	900	–	900
FA (deg)	90	30	90	8	150	9	90	8

GE = General Electric; T1w = T1-weighted; FLAIR = Fluid Attenuated Inversion Recovery; T2w = T2-weighted; FOV = field of view; TR = repetition time; TE = echo time; TI = inversion time; FA = flip angle; TFE = transient field echo; IR = inversion recovery; FSPGR = fast spoiled gradient echo; MPRAGE = magnetization prepared rapid gradient echo; FFE = fast field echo.




FIGURE 1: On the left, a scatter plot for the comparison of whole-brain volumes (in mL) in HC for the different software packages. On the right, a scatter plot for the comparison of GM volume results (in mL) in HC for the different softwares. GM = gray matter.




FIGURE 2: In the first row, scatter plots for the comparisons of whole-brain volume results on HC for the different software packages and separately for each Center (in each column). In the second row, scatter plots for the comparisons of GM volumes on HC for the different software packages and separately for each Center (in each column). Blue circles are for the SIENAX atrophy results on the y-axis, while red circles are for SPM-v12.

Considering all datasets together, we found that the ratio of females to males included was significantly different between MS patients and HC. Separately, for the majority of the datasets considered, no significant differences in age or sex were found between the two groups ( $P$  values ranging from 0.32 to 0.50), except for center C, where patients were significantly older than HC. Center C showed a significant sex difference between MS patients and HC.

Disease duration was significantly different between datasets from centers B and C, lesion load was significantly

different between patients of centers C and D, and EDSS scores were significantly different between several dataset pairs: A and D, B and C, B and D, and C and D.


At follow-up (mean follow-up interval =  $0.98 \pm 0.24$  years for MS,  $1.05 \pm 0.21$  years for HC;  $P = 0.07$ ), median EDSS was 1.5 (range = 0–4.5,  $P = 0.1$  vs. baseline) and 12 MS patients had worsened clinically (EDSS score increase  $\geq 1.5$  when baseline EDSS was 0,  $\geq 1.0$  when EDSS at baseline was  $< 6.0$ , and  $\geq 0.5$  when EDSS at baseline was  $\geq 6.0$ ).

**TABLE 3. Intra-class Correlation Coefficients Evaluated Separately for Each Center, for Cross-Sectional Whole-Brain and GM Segmentations**

ICC		Jim-v8 SIENAX		Jim-v8 SPM-v12		SIENAX SPM-v12	
		Whole-brain	GM	Whole-brain	GM	Whole-brain	GM
HC	Center A	0.25	0.52	0.78*	0.70*	0.23	0.54
	Center B	0.22	0.48	0.83*	0.86*	0.17	0.51
	Center C	0.19	0.32	0.92*	0.87*	0.16	0.37
	Center D	0.12	0.29	0.93*	0.81*	0.14	0.40
MS	Center A	0.23	0.47	0.97*	0.76*	0.21	0.50
	Center B	0.17	0.56	0.80*	0.90*	0.13	0.59
	Center C	0.14	0.33	0.86*	0.82*	0.11	0.45
	Center D	0.18	0.39	0.94*	0.62*	0.16	0.58

Abbreviations: ICC=Intra-class correlation coefficient; GM = gray matter; HC = healthy controls; MS = multiple sclerosis; SPM = Statistical Parametric Mapping.

\* $P < 0.05$ .



**FIGURE 3:** In the first row, the distributions of the whole-brain volumes/volume-fractions for MS and HC obtained using the different software packages (in the three columns). In the second row, the GM volume/volume-fraction distributions for MS and HC obtained using the different software packages (in the three columns). BRAINV = brain volume fraction; BRAINV = brain volume; GMVF = gray matter volume fraction; GMV = gray matter volume; MS = multiple sclerosis; HC = healthy controls.

### Assessment of Cross-Sectional Atrophy Measures

For the cross-sectional assessment, we found a significant agreement between whole-brain volumes obtained by SPM-v12 and Jim-v8 for both HC (ICC = 0.93) and MS patients (ICC = 0.84), while no significant agreements were found in the comparisons between SIENAX and both SPM-v12

( $P = 0.19$ ) and Jim-v8 ( $P = 0.21$ ) (Fig. 1), with a systematic shift of SIENAX whole-brain volumes over lower values. Similarly, for GM cross-sectional atrophy, we found a significant agreement between the GM volumes obtained by SPM-v12 and Jim-v8 for both HC (ICC = 0.66) and MS patients (ICC = 0.90), while no significant agreement was found for

**TABLE 4. Sample Size at Three Different Power Levels in Detecting an Effect at the 0.05 Alpha Level on Longitudinal Changes of Whole-Brain and GM Volumes for Each Software Package**

Power level	70%		80%		90%	
	Sample size					
	Whole-brain	GM	Whole-brain	GM	Whole-brain	GM
SIENA/SIENA-XL	62	152	79	193	105	258
SPM-v12	384	549	488	699	653	935
Jim-v8	58	163	73	207	98	277

GM = gray matter; SPM = Statistical Parametric Mapping.

the comparisons among SIENAX and both SPM-v12 ( $P = 0.29$ ) and Jim-v8 ( $P = 0.32$ ) (Fig. 1). Considering each Center separately (Fig. 2), SPM-v12 and Jim-v8 showed again the highest agreements both for whole-brain and GM volumes for HC and MS patients, as shown in Table 3. No significant agreements were found in the comparisons between SIENAX and both SPM-v12 and Jim-v8 atrophy results for each Center individually and for both whole-brain (center A:  $P = 0.18$  and  $P = 0.21$ ; center B:  $P = 0.16$  and  $P = 0.32$ ; center C:  $P = 0.09$  and  $P = 0.12$ ; center D:  $P = 0.25$  and  $P = 0.43$ ) and GM volume (center A:  $P = 0.21$  and  $P = 0.22$ ; center B:  $P = 0.11$  and  $P = 0.33$ ; center C:  $P = 0.15$  and  $P = 0.13$ ; center D:  $P = 0.36$  and  $P = 0.53$ ).

Regarding the difference between MS patients and HC (Fig. 3), all software tools showed low effect sizes (Cohen's  $d = -0.40, -0.32, -0.3$ , for SPM-v12, Jim-v8, and SIENAX, respectively) for whole-brain atrophy quantification, while SPM-v12 and Jim-v8 showed the highest effect sizes for cross-sectional GM atrophy (Cohen's  $d = -0.63$  and  $-0.61$ , respectively) compared to SIENAX (Cohen's  $d = -0.53$ ). All software applications showed a significant difference for both whole-brain and GM volume results between MS patients and HC.

### Assessment of Longitudinal Atrophy Measures

For longitudinal whole-brain atrophy assessment, SPM-v12 and SIENA showed significant agreement for both HC (ICC = 0.62) and MS patients (ICC = 0.43), while no significant agreement was found in the comparisons between Jim-v8 and both SPM-v12 and SIENA whole-brain volume changes (all ICCs < 0.1,  $P = 0.54$  and  $P = 0.37$ , respectively). For longitudinal GM atrophy quantification, SPM-v12 and Jim-v8 showed a significant agreement for MS patients (ICC = 0.59), while a lower value of agreement was found for GM volumes (ICC = 0.35) in HC, as well as between SIENA-XL and SPM-v12 (ICC = 0.4 for MS; ICC = 0.26,  $P = 0.05$  for HC). No significant agreement was found for longitudinal GM atrophy quantification between SIENA-XL and Jim-v8 results (ICC = 0.12,  $P = 0.63$ ).

Jim-v8 and SIENA-XL showed the smallest and comparable sample size requirements for both whole-brain and GM longitudinal atrophy assessment at the different power levels. Table 4 shows the sample size requirements for each software package at each power level.

### Discussion

In this work, we aimed to compare three of the available methods for whole-brain and GM atrophy measurements on a multicenter dataset, in order to guide the selection of a suitable atrophy processing pipeline for large MS studies. Using the INNI dataset, we found good agreement between SPM-v12 and Jim-v8, which also better separated GM atrophy distribution between MS patients and HC in comparison to the third software package (SIENAX). However, the newly proposed SIENA(XL) and Jim-v8 required the smallest sample size for longitudinal atrophy quantification.

The high agreements found between SPM-v12 and Jim-v8 for cross-sectional whole-brain and GM atrophy quantification may be explained by the fact that the implementation of both methods was similar. These pipelines started with the same International Consortium from Brain Mapping (ICBM) atlas<sup>30</sup> as a prior tissue type probability map, which was registered to the T1-weighted image. Then, the T1-weighted image was automatically segmented into GM, WM, and cerebrospinal fluid, giving spatially normalized volumes (see Supplemental Material S1 for a detailed description).<sup>31</sup> On the other hand, with SIENAX, voxels within the brain were classified based on image intensities using a hidden Markov random field model, and tissue volumes were normalized using a scaling factor accounting for head size.<sup>32</sup>

The ICC reliability indices between the atrophy results for each software package, estimated separately for each center, were as expected when considering all centers together: the comparisons for the different software packages did not change for any specific center. Thus, pooling T1-weighted images with similar quality from different MRI acquisition centers did not affect or introduce a bias into the degree of



agreement between the software packages. In this study, even though the acquisition was not standardized, the 3D T1-weighted anatomical brain images from the INNI database, provided as input to the atrophy pipelines, were similar between the centers especially in terms of resolution and field of view (no relevant effect on lesion filling). Thus, our findings here may endorse the importance of large multicenter quantitative studies of brain tissue atrophy in MS with high-resolution T1-weighted images, even if they are acquired without using highly standardized acquisition protocols. However, a high degree of standardization of the different MRI acquisition protocols at the different centers and data harmonization procedures are strongly recommended if the most reliable results are to be obtained.<sup>10,33,34</sup>

For analyses at group level, both whole-brain and GM atrophy measures obtained by all software packages facilitated differentiation between HC and MS patients. However, it is important not to combine measures obtained using different pipelines within the same analysis, even for large studies due to their different levels of accuracy and precision in estimating brain atrophy.<sup>11</sup> Moreover, the different software packages did not show similar strengths in the assessment of between-group differences (effect sizes), especially for GM cross-sectional atrophy quantification. This is likely because GM volume is smaller than the whole-brain volume, and therefore subject to greater measurement errors as a percentage of any real change in volume.<sup>2</sup> Moreover, the measurement of GM atrophy in MS could be heavily affected by disease-specific technical challenges (eg presence of T1-hypointense MS lesions), more so than for whole-brain volume quantification.<sup>35</sup>

In contrast to the cross-sectional results, when SPM-v12 and SIENA/SIENA-XL were applied longitudinally, they showed a significant agreement for whole-brain and GM atrophy values. In this case, both pipelines were initialized in a similar way: they performed a longitudinal pairwise registration to align the baseline and follow-up 3D T1-weighted scans in a half-way space and produced a result consisting of a direct estimation of whole-brain volume change in this space (see Supplemental Material S1 for methodological details). The longitudinal pipeline from Jim-v8 also performed a half-way registration between baseline and follow-up images and used the Jacobian determinants of the deformation field, as in SPM-v12 longitudinal pipeline, but only when estimating GM volume change.<sup>26</sup> Thus, Jim-v8 showed significant agreement with SPM-v12 only for GM atrophy quantification.

In the majority of cases, we found that the agreement between analysis methods obtained for MS patients was higher than for HC, for both cross-sectional and longitudinal atrophy. This may be due to the fact that we expected smaller cross-sectional brain volume variations between subjects, and smaller longitudinal changes in atrophy in HC than in patients with MS. Thus, not all pipelines may be sensitive

enough to capture these smaller variations, leading to lower levels of agreement in HC.

For the use in a clinical setting, atrophy assessment should be both highly sensitive and precise. In this study, we found that the Jim-v8 and SIENA(XL) longitudinal pipelines, for both whole-brain and GM atrophy quantification, required comparable and the smallest sample sizes at all power levels compared to the third software, making these tools appealing for application in MS studies. This was due to the lower difference for SPM-v12 between the means of the distribution of atrophy rates for HC and MS patients relative to the standard deviation found for HC, in comparison to the other two software packages (0.2 for whole-brain assessments against 0.47 and 0.45 for Jim-v8 and SIENA, respectively). For SIENA whole-brain atrophy assessment, our findings on sample size requirements may be in line with previous literature.<sup>36,37</sup> The requirement of a small sample size is also desirable for the creation of normative data for atrophy measures, to be used in individualized medicine when evaluating treatment effects.<sup>38</sup> However, for SPM-v12 longitudinal atrophy assessment, we need to point out that the pipeline was built in-house using a combination of the longitudinal pairwise registration (a tool already implemented in SPM) and the Jacobian integration technique. Thus, longitudinal atrophy assessment is not part of an officially released processing pipeline.

From empirical evaluations obtained with the use of these tools, while having access to a free license (as in the case of SIENA(X)) is desirable, the ease of integration into the clinical routine (which is more straightforward for Jim-v8) and the ease of use (as in the case of both Jim-v8 and SPM-v12) are additional important considerations when selecting an atrophy processing pipeline. Especially for nonexpert users, the possibility to have a simple graphical user interface to guide the entire atrophy procedure is desirable, with respect to the use of a pipeline from the command-line interface. However, in research settings, the versatility of use and the free license are often desirable even at the expense of a less user-friendly toolbox.

### Limitations

One limitation of this study was that it could not provide information about the accuracy and precision of the atrophy assessment methods investigated, due to the lack of a test-retest dataset or a comparison with ground truth, as it has been achieved in a previous study on a smaller cohort.<sup>11</sup> However, the analyses performed in this study focused on the application of currently available techniques to a large dataset, in order to compare their performances in detecting whole-brain and GM atrophy on cross-sectional and longitudinal multicenter MRI data. Moreover, we enrolled only the RR MS phenotype to focus on the software comparison, limiting the heterogeneity due to the disease. Further investigations should include also progressive forms of the disease. Finally, brain alterations due to the normal aging could affect atrophy

measures. In this study, we tried to overcome this issue by including a group of age-matched HC for the cross-sectional comparisons and we considered a limited follow-up period of 1 year. Furthermore, the SIENA-XL toolbox is a recently published longitudinal atrophy method not publicly available that has been included in this study under a permission of the developers. Currently, this is a limitation for the reproducibility of this study that would need to be overcome in the future when the software will be freely available.

Even if the choice not to include Freesurfer in the comparison could be seen as a limitation, in this study we decided to focus on two main aspects: 1) to restrict the comparison to those software that resulted as well-performing from our previous study on a single center and smaller sample size<sup>11</sup>; 2) to avoid including methods that are not specifically implemented and optimized for a volumetric quantification of brain tissues (as Freesurfer). Moreover, the inclusion of other atrophy measures as cortical thickness did not allow a direct comparison among the results of the different pipelines evaluated and goes beyond the purpose of this study: to focus on tools that would give an easy estimation of both whole-brain and gray matter (volumetric) atrophy measures for a possible future introduction in the clinical scenario.

## Conclusion

Using the INNI dataset, we compared the performance of different atrophy tools on a large sample of patients acquired by multiple centers. We found good agreement between SPM-v12 and Jim-v8 atrophy results, while Jim-v8 and SIENA(XL) may provide the smallest estimated sample size for longitudinal atrophy quantification. The findings obtained in this study should be considered when selecting the appropriate brain atrophy pipeline for MS studies.

## Acknowledgment

Open access funding provided by BIBLIOSAN.

## References

- Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. *Nat Rev Dis Primers* 2018;4(1):43.
- Rocca MA, Battaglini M, Benedict RH, et al. Brain MRI atrophy quantification in MS: From methods to clinical application. *Neurology* 2017; 88(4):403-413.
- Damjanovic D, Valsasina P, Rocca MA, et al. Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: A multicenter study. *AJNR Am J Neuroradiol* 2017;38(1): 18-24.
- De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. *Neurology* 2003;60(7):1157-1162.
- Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: A longitudinal study. *Ann Neurol* 2008;64(3):255-265.
- Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. *Mult Scler* 2016;22(10):1297-1305.
- Allanach JR, Farrell JW, Mesidor M, Karimi-Abdolrezaee S. Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review. *Mult Scler* 2022;28(1):29-48.
- Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. *Ann Neurol* 2013;75:43-49.
- Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X. Treating relapsing-remitting multiple sclerosis: Therapy effects on brain atrophy. *J Neurol* 2015;262(12):2617-2626.
- Sastre-Garriga J, Pareto D, Battaglini M, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nat Rev Neurol* 2020;16(3):171-182.
- Storelli L, Rocca MA, Pagani E, et al. Measurement of whole-brain and gray matter atrophy in multiple sclerosis: Assessment with MR imaging. *Radiology* 2018;288(2):554-564.
- Beadnall HN, Wang C, Van Hecke W, Ribbens A, Billiet T, Barnett MH. Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: Towards clinical integration? *Ther Adv Neurol Disord* 2019;12: 1756286418823462.
- Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: A review. *J Neurol* 2009;256(9):1397-1412.
- Steenwijk MD, Amiri H, Schoonheim MM, et al. Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. *Neuroimage Clin* 2017;15:843-853.
- Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *J Neurol* 2013;260(10):2458-2471.
- Derakhshan M, Caramanos Z, Giacomini PS, et al. Evaluation of automated techniques for the quantification of gray matter atrophy in patients with multiple sclerosis. *Neuroimage* 2010;52(4):1261-1267.
- Ge Y, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis: Fractional volumetric analysis of gray matter and white matter. *Radiology* 2001;220(3): 606-610.
- Kazemi K, Noorizadeh N. Quantitative comparison of SPM, FSL, and Brainsuite for brain MR image segmentation. *J Biomed Phys Eng* 2014; 4(1):13-26.
- Sanfilippo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. *Neurology* 2006;66(5):685-692.
- Filippi M, Tedeschi G, Pantano P, et al. The Italian neuroimaging network initiative (INNI): Enabling the use of advanced MRI techniques in patients with MS. *Neurol Sci* 2017;38(6):1029-1038.
- Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. *Neurology* 1996;46:907-911.
- Storelli L, Rocca MA, Pantano P, et al. MRI quality control for the Italian neuroimaging network initiative: Moving towards big data in multiple sclerosis. *J Neurol* 2019;266(11):2848-2858.
- Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. *Brain* 2019;142(7):1858-1875.
- Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. *Hum Brain Mapp* 2011;33:2062-2071.
- Battaglini M, Jenkinson M, De Stefano N, Alzheimer's Disease Neuroimaging I. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI. *Hum Brain Mapp* 2018;39(3): 1063-1077.
- [http://www.xinapse.com/Manual/brain\\_atrophy\\_intro.html](http://www.xinapse.com/Manual/brain_atrophy_intro.html)
- FSL-FMRIB. <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki>

28. <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>
29. Cohen J. *Statistical power analysis for the behavioral sciences* (2nd ed). Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
30. Mazziotta J, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: International consortium for brain mapping (ICBM). *Philos Trans R Soc Lond B Biol Sci* 2001;356(1412):1293-1322.
31. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage* 2005; 26(3):839-851.
32. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. *IEEE Trans Med Imaging* 2001;20(1):45-57.
33. De Stefano N, Battaglini M, Pareto D, et al. MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. *Neuroimage Clin.* 2022;34:102972.
34. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurol* 2021;20(8):653-670.
35. Amiri H, de Sitter A, Bendfeldt K, et al. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. *NeuroImage* 2018;19:466-475.
36. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology* 2010;74(23):1868-1876.
37. Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. *Neuroimage Clin.* 2014;4:10-17.
38. Battaglini M, Gentile G, Luchetti L, et al. Lifespan normative data on rates of brain volume changes. *Neurobiol Aging* 2019;81:30-37.